COMPANY

Synnovation Therapeutics

Location: Wilmington, DE · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Pancreatic Cancer Pancreatic Acinar Carcinoma SNV1521 DB-1310

Raises and deals from press releases

Deal Novartis deal · $2B upfront · announced Mar 20, 2026 Company release ↗
Source quote
- Mar 20, 2026 · Company release ↗
  “Novartis to acquire Synnovation Therapeutics’s pan-mutant selective PI3Kα inhibitor program - Synnovation will receive total cash consideration of up to $3 billion, consisting of $2 billion in upfront cash and up to $1 billion in development”

From the company’s own releases; this list is partial. All raises and deals

Feb 23, 2024 Trial start Phase 1: SNV1521 in Participants With Advanced Solid Tumors source ↗
2026-09 Trial start Phase 1: First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer source ↗

2027-12 (ESTIMATED) · Phase 1 · SNV1521 in Participants With Advanced Solid Tumors · NCT06220864
Jun 1, 2029 (ESTIMATED) · Phase 1 · First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer · NCT07756281

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07756281	First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer	Phase 1	Not yet recruiting	2026-09	Jun 1, 2029 (estimated)
NCT06220864	SNV1521 in Participants With Advanced Solid Tumors	Phase 1	Recruiting	Feb 23, 2024	2027-12 (estimated)